These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17227285)

  • 1. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.
    Dunlop J; Marquis KL; Lim HK; Leung L; Kao J; Cheesman C; Rosenzweig-Lipson S
    CNS Drug Rev; 2006; 12(3-4):167-77. PubMed ID: 17227285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
    Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
    Zaniewska M; McCreary AC; Przegaliński E; Filip M
    Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease.
    Navailles S; Lagière M; Roumegous A; Polito M; Boujema MB; Cador M; Dunlop J; Chesselet MF; Millan MJ; De Deurwaerdère P
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):593-606. PubMed ID: 22717119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.
    Grauer SM; Graf R; Navarra R; Sung A; Logue SF; Stack G; Huselton C; Liu Z; Comery TA; Marquis KL; Rosenzweig-Lipson S
    Psychopharmacology (Berl); 2009 May; 204(1):37-48. PubMed ID: 19107466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
    Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonin 2C receptor agonist WAY-163909 attenuates ketamine-induced hypothermia in mice.
    Murphy TJ; Murnane KS
    Eur J Pharmacol; 2019 Jan; 842():255-261. PubMed ID: 30412729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
    Siuciak JA; Chapin DS; McCarthy SA; Guanowsky V; Brown J; Chiang P; Marala R; Patterson T; Seymour PA; Swick A; Iredale PA
    Neuropharmacology; 2007 Feb; 52(2):279-90. PubMed ID: 16949622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists.
    Ennis MD; Hoffman RL; Ghazal NB; Olson RM; Knauer CS; Chio CL; Hyslop DK; Campbell JE; Fitzgerald LW; Nichols NF; Svensson KA; McCall RB; Haber CL; Kagey ML; Dinh DM
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2369-72. PubMed ID: 12824036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.
    Rosenzweig-Lipson S; Comery TA; Marquis KL; Gross J; Dunlop J
    Handb Exp Pharmacol; 2012; (213):147-65. PubMed ID: 23027415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems.
    Giorgetti M; Tecott LH
    Eur J Pharmacol; 2004 Mar; 488(1-3):1-9. PubMed ID: 15044029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
    Bromidge SM; Dabbs S; Davies DT; Davies S; Duckworth DM; Forbes IT; Gaster LM; Ham P; Jones GE; King FD; Mulholland KR; Saunders DV; Wyman PA; Blaney FE; Clarke SE; Blackburn TP; Holland V; Kennett GA; Lightowler S; Middlemiss DN; Trail B; Riley GJ; Wood MD
    J Med Chem; 2000 Mar; 43(6):1123-34. PubMed ID: 10737744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.
    Andrews MD; Fish PV; Blagg J; Brabham TK; Brennan PE; Bridgeland A; Brown AD; Bungay PJ; Conlon KM; Edmunds NJ; af Forselles K; Gibbons CP; Green MP; Hanton G; Holbrook M; Jessiman AS; McIntosh K; McMurray G; Nichols CL; Root JA; Storer RI; Sutton MR; Ward RV; Westbrook D; Whitlock GA
    Bioorg Med Chem Lett; 2011 May; 21(9):2715-20. PubMed ID: 21195614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT2 ligands in the treatment of anxiety and depression.
    Quesseveur G; Nguyen HT; Gardier AM; Guiard BP
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1701-25. PubMed ID: 22917059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment.
    Zaniewska M; McCreary AC; Wydra K; Filip M
    Synapse; 2010 Jul; 64(7):511-9. PubMed ID: 20196140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of methylated arylazepine compounds for PET imaging of 5-HT(2c) receptors.
    Granda ML; Carlin SM; Moseley CK; Neelamegam R; Mandeville JB; Hooker JM
    ACS Chem Neurosci; 2013 Feb; 4(2):261-5. PubMed ID: 23421677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist.
    Kimura Y; Hatanaka K; Naitou Y; Maeno K; Shimada I; Koakutsu A; Wanibuchi F; Yamaguchi T
    Eur J Pharmacol; 2004 Jan; 483(1):37-43. PubMed ID: 14709324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.